Drugs and Vaccines for Developing Countries

The Oxford Handbook of the Economics of the Biopharmaceutical Industry

Volumn , Issue , 2012, Pages

  Towse, Adrian ^a,b   Keuffel, Eric ^c   Kettler, Hannah E ^d   Ridley, David B ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c TEMPLE UNIVERSITY   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

Affordable medicine; Global medicines; Neglected diseases; New drugs; Research input

Indexed keywords

EID: 84925070879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780199742998.013.0010     Document Type: Chapter

References (109)

1. Access to Medicine Foundation. 2010. Access to Medicine Index 2010. Available at http://www.accesstomedicineindex.org/sites/www.accesstomedicineindex.org/files/publication/Access_to_Medicine_Index_2010.pdf (accessed November 2011).
2. Arrow, K.J., C. Panosian, and H. Gelband, eds. 2004. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington, DC: The National Academies Press.
3. Attaran, A. 2004. "How Do Patents and Economic Policies Affect Access to Essential Medicines in Developing Countries?" Health Affairs 23(3): 155- 166.
4. Babar, Z.U.D., M.I.M. Ibrahim, H. Singh, N.I. Bukahri, and A. Creese. 2007. "Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia." PLoS Medicine 4(3): e82.
5. Banerjee, A., A. Hollis, and T. Pogge. 2010. "The Health Impact Fund: Incentives for Improving Access to Medicines." Lancet 375(9709): 166-169.
6. Barninghausen, T., D.E. Bloom, D. Canning, A. Friedman, O. Levine, J. O'Brien, L. Privor-Dumm, and D. Walker. 2008. The Economics Case for Expanding Vaccination Coverage of Children. Copenhagen, Denmark: Copenhagen Consensus Center.
7. Berndt, E.R., R. Glennerster, M.R. Kremer, J. Lee, R. Levine, G. Weizsacker, and H. Williams. 2007. "Advance Market Commitments for Vaccines Against Neglected Diseases: Estimating Costs and Effectiveness." Health Economics 16(5): 491-511.
8. BIO Ventures for Global Health. 2006. Tuberculosis Vaccines: The Case for Investment. Washington, DC: BVGH.
9. BIO Ventures for Global Health. 2009. BVGH Global Health Primer. Washington, DC: BVGH.
10. Business Monitor International. 2010. India Pharmaceuticals & Healthcare Report Q3 2010. Industry Report & Forecasts Series. London: BMI.
11. Cameron, A., M. Ewen, D. Ross-Degnan, D. Ball, and R. Laing 2009. "Medicine Prices, Availability, and Affordability in 36 Developing and Middle-Income Countries: A Secondary Analysis." The Lancet 373(9659): 240-249.
12. Cavanagh, J. 2010. Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas. London: Business Insights.
13. Center for Global Development. 2007. A Risky Business: Saving Money and Improving Global Health Through Better Demand Forecasts. Washington, DC: CGD.
14. Cohen, J. 2009. "Drug Approvals for Neglected Diseases Increase Along With More R&D Funding." Tufts Center for the Study of Drug Development 11: 1-4.
15. Commission on Intellectual Property Rights, Innovation and Public Health. 2006. Public Health, Innovation and Intellectual Property Rights. Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva: WHO.
16. Commission on Macroeconomics and Health. 2001. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Chaired by Jeffrey D. Sachs. Geneva: World Health Organization.
17. Dalberg Global Development Advisors and the MIT-Zaragoza International Logistics Program. 2008. Private Sector Role in Health Supply Chains: Review of the Role and Potential for Private Sector Engagement in Developing Country Health Supply Chains. Technical partner paper 13. Washington, DC: Results for Development Institute.
18. Danzon P.M. 1998. "The Economics of Parallel Trade." PharmacoEconomics, 13(3): 293-304
19. Danzon, P.M., A. Mulcahy, and A. Towse. 2011. Pharmaceutical Prices in Emerging Markets. NBER Working Paper 17174. Cambridge, MA: National Bureau of Economic Research.
20. Danzon, P.M., and A. Towse. 2003. "Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents." International Journal of Health Care Finance and Economics 3(3): 183-205.
21. Dentzer, S. 2009. "Eliminating Neglected Diseases in Poor Countries: A Conversation with Andrew Witty." Health Affairs 28(3): w411-w416.
22. DiMasi, J., and H.G. Grabowski. 2004. Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D. Submission to the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva: World Health Organization.
23. DiMasi, J.A., R.W. Hansen, and H.G. Grabowski. 2003. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics 22(2): 151-185.
24. Dolgin, E. 2010. "African Networks Launch to Boost Clinical Trial Capacity." Nature Medicine 16(1): 8.
25. Farlow, A., D.W. Light, R. Mahoney, and R. Widdus. 2005. Concerns Regarding the Center for Global Development Report 'Making Markets for Vaccines. Submission to the Commission on Intellectual Property Rights, Innovation, and Public Health. Geneva: World Health Organization.
26. Fink, C. 2001. "Patent Protection, Transnational Corporations, and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry." Journal of Industry, Competition and Trade 1(1): 101-121.
27. Frew, S.E., H.E. Kettler, and P.A. Singer. 2008. "The Indian and Chinese Health Biotechnology Industries: Potential Champions of Global Health?" Health Affairs 27(4): 1029-1041.
28. Frew, S.E., V.Y. Liu, and P.A. Singer. 2009. "A Business Plan to Help the 'Global South' in Its Fight Against Neglected Diseases." Health Affairs 28(6): 1760-1773.
29. Frick, K.D., E.L. Keuffel, and R.J. Bowman. 2001. "Epidemiological, Demographic, and Economic Analyses: Measurement of the Value of Trichiasis Surgery in the Gambia." Ophthalmic Epidemiology 8(2-3): 191-201.
30. Global Alliance for TB Drug Development. 2001. The Economics of TB Drug Development. New York: GATBD.
31. Global Forum for Health Research. 2002. The 10/90 Report on Health Research 2001-2002. Geneva: GFHR.
32. Global Forum for Health Research. 2008. Health Partnerships Review: Focusing Collaborative Efforts on Research and Innovation for the Health of the Poor. Geneva: GFHR.
33. Goldstein, J. 2009, October 28. "Where GSK Is Cutting Sales Reps, and Where It's Adding Them." Wall Street Journal (Health Blog).
34. Goodman, C., S.P. Kachur, S. Abdulla, P. Bioland, and A. Mills. 2009. "Concentration and Drug Prices in the Retail Market for Malaria Treatment in Rural Tanzania." Health Economics 18(6): 727-742.
35. Grabowski, H.G., D.B. Ridley, and J.L. Moe. 2009. "Priority Review Vouchers to Encourage Innovation for Neglected Diseases." In Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific. K. Eggleston, ed. Washington, DC: Brookings Institution Press.
36. Gray, A., P. Fenn, M. Garau, C. Pritchard, E. Godber, and A. Towse. 2006. Donor Investment Choices for Global Health: Modelling the Value for Money of Investing in Product Development Public Private Partnerships as Compared to Other Health Care and Non-Health Care Interventions. OHE Consulting Summary Report. London: Office of Health Economics.
37. Greenberg, H., S.U. Raymond, and S.R. Leeder. 2005. "Cardiovascular Disease and Global Health: Threat and Opportunity." Health Affairs doi:10.1377/hlthaff.w5.31.
38. Hecht, R., P. Wilson, and A. Palriwala. 2009. "Improving Health R&D Financing for Developing Countries: A Menu of Innovative Policy Options." Health Affairs 28(4): 974-985.
39. Holmes, C.B., W. Coggin, D. Jamieson, H. Mihm, R. Granich, P. Savio, M. Hope, C. Ryan, M. Moloney-Kitts, E.P. Goosby, and M. Dybul. 2010. "Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs." Journal of the American Medical Association 304(3): 313-320.
40. Hsu, J.C., and E.S. Schwartz. 2008. "A Model of R&D Valuation and the Design of Research Incentives." Insurance: Mathematics and Economics 43(3): 350-367.
41. IFPMA (International Federation of Pharmaceutical Manufacturers and Associations). 2010. Developing World Health Partnerships Directory 2010. Geneva: IFPMA.
42. IMPACT (International Medical Products Anti-Counterfeiting Taskforce). 2006. "Counterfeit Medicines: An Update on Estimates." Geneva: World Health Organization.
43. Jamison D.T., J.G. Breman, A.R. Measham, et al., eds. 2006. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank.
44. Jamison, D.T, P. Jha, and D.E. Bloom. 2009. "Copenhagen Consensus 2008 Challenge Paper: Diseases." In Global Crises, Global Solutions. 2nd. ed. B. Lomborg, ed., 126-179. Cambridge: Cambridge University Press.
45. Jena, A.B., S. Mechoulan, and T.J. Philipson. (2010). "Altruism and Innovation in Health Care." Journal of Law and Economics 53(3): 497-518.
46. Kates, J., A. Wexler, E. Leif, and V. Seegobin. 2010. Donor Funding for Health in Low- and Middle-Income Countries. Washington, DC: Kaiser Family Foundation.
47. Kesselheim, A.S. 2008. "Drug Development for Neglected Diseases: The Trouble With FDA Review Vouchers." New England Journal of Medicine 359: 1981-1983.
48. Kettler, H.E. 2000. "Narrowing the Gap Between Provision and the Need for Medicines in Developing Countries." London: Office of Health Economics.
49. Kettler, H., and C. Collins. 2002. Using Innovative Action to Meet Global Health Needs Through Existing Intellectual Property Regimes. Study Paper 2b London: Commission on Intellectual Property Rights.
50. Kettler, H., and A. Towse. 2002. Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty. London: Office of Health Economics.
51. Kettler, H., K. White, and S. Jordon. 2003. Valuing Industry Contributions to Public Private Partnerships for Health Product Development. Geneva: Initiative on Public-Private Partnerships for Health.
52. Kremer, M. 1998. "Patent Buyouts: A Mechanism for Encouraging Innovation." Quarterly Journal of Economics 113(4): 1137-1167.
53. Kremer, M. 2000. "Creating Markets for New Vaccines Part II: Design Issues." NBER Working Papers 7717. Cambridge, MA: National Bureau of Economic Research.
54. Kremer, M. 2002. "Pharmaceuticals and the Developing World." Journal of Economic Perspectives 16(4): 67-90.
55. Kremer, M., and R. Glennerster. 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, NJ: Princeton University Press.
56. Kremer, M., A. Towse, and H. Williams. 2005. Briefing Note on Advance Purchase Commitments. London: UK Department International Development (DFID) Health Systems Resource Centre. Available at http://www.who.int/intellectualproperty/submissions/MichealKremerKTW_CIPIH_submit_2.pdf (accessed November 2011).
57. Kumar Sharma, E. "Takeover Therapy; Piramal's Domestic Formulations Business Becomes the Latest-and Most Expensive-Acquisition of an Indian Drug Business by a Global Pharma Major. As the Stakes Get Higher, Who's Next?" Business Today (New Delhi), June 27, 2010.
58. Kyle, M. 2008. "Strategic Responses to Parallel Trade." The B.E. Journal of Economic Analysis & Policy 11(2): Article 2.
59. Kyle, M., and A. McGahan. 2009. "Investments in Pharmaceuticals Before and After TRIPS." NBER Working Paper 15468. Cambridge, MA: National Bureau of Economic Research.
60. Kyle, M., and D.B. Ridley. 2007. "Would Greater Transparency and Uniformity of Health Care Prices Benefit Poor Patients?" Health Affairs 26(5): 1384- 1391.
61. Lanjouw J. 1998. "Introduction of Pharmaceutical Product Patents in India: 'Heartless Exploitation of the Poor and Suffering'?" NBER Working Paper 6366. Cambridge, MA: National Bureau of Economic Research.
62. Lanjouw, J. 2006. "A Patent Policy Proposal for Global Diseases." Innovations: Technology, Governance, Globalization 1(1): 108-114.
63. Laxminarayan, R., and H. Gelband. 2009. "A Global Subsidy: Key to Affordable Drugs for Malaria?" Health Affairs 28(4): 949-961.
64. Laxminarayan, R., M. Over, and D.L. Smith. 2006. "Will a Global Subsidy of New Antimalarials Delay the Emergence of Resistance and Save Lives?" Health Affairs 25(2): 325-336.
65. Laxminarayan, R., I.W.H. Parry, D.L. Smith, and E.Y. Klein. 2010. "Should New Antimalarial Drugs Be Subsidized?" Journal of Health Economics 29: 445- 456.
66. Levine, R. 2007. A Risky Business: Saving Money and Improving Global Health Through Better Demand Forecasts. Washington, DC: Center for Global Development.
67. Levine, R., M. Kremer, and A. Albright. 2005. Making Markets for Vaccines: Ideas to Action. Report of the Center for Global Development Advance Market Commitment Working Group. Available at http://www.cgdev.org/doc/books/vaccine/MakingMarkets-complete.pdf (accessed November 2011).
68. Levine, R., J. Pickett, N. Sekhri, and P. Yadav. 2008. "Demand Forecasting for Essential Medical Technologies." American Journal of Law and Medicine 34: 225-255.
69. Lichtenberg, F.R., and J. Waldfogel. 2008. "Does Misery Love Company? Evidence from Pharmaceutical Markets Before and After the Orphan Drug Act." Michigan Telecommunications and Technology Law Review 15: 335-357.
70. Loftus, P. 2010, June 8. "Eli Lilly Sets Plans for Emerging Markets." Wall Street Journal (Online).
71. Love, J., and T. Hubbard. 2007. "The Big Idea: Prizes to Stimulate R&D for New Medicines." Chicago-Kent Law Review 82(3): 1519-1554.
72. Médecins Sans Frontières. 2011. Untangling the Web of Antiretroviral Price Reductions. 14th ed. Geneva: MSF.
73. Moe, J., H.G. Grabowski, and D.B. Ridley. 2009. "FDA Review Vouchers" [Correspondence]. New England Journal of Medicine 360: 837-838.
74. Moran, M. 2005. "A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need." PLoS Medicine 2(9): e302.
75. Moran, M., J. Guzman, K. Henderson, L. Abela-Oversteegen, L. Wu, B. Omune, D. Gouglas, N. Chapman, and F. Zmudzki. 2011. Neglected Disease Research and Development: Is the Global Financial Crisis Changing R&D? Global Funding of Innovation for Neglected Diseases (G-Finder). London: Policy Cures, London International Development Centre.
76. Onwujekwe, O., K. Hanson, and J. Fox-Rushby. 2004. "Inequalities in Purchase of Mosquito Nets and Willingness to Pay for Insecticide-Treated Nets in Nigeria: Challenges for Malaria Control Interventions." Malaria Journal 3(1): 6.
77. Oxfam International. 2007. Investing for Life: Meeting Poor People's Needs for Access to Medicines Through Responsible Business Practices. Oxfam Briefing Paper 109. Oxford, UK: Oxfam.
78. Patouillard, E., K.G. Hanson, and C.A. Goodman. 2010. "Retail Sector Distribution Chains for Malaria Treatment in the Developing World: A Review of the Literature." Malaria Journal 9: 50.
79. Pecoul B., P. Chirac, P. Trouiller, and J. Pinel. 1999. "Access to Essential Drugs in Poor Countries: A Lost Battle?" Journal of the American Medical Association 281: 361-367.
80. Pogge, T., and A. Hollis. 2008. The Health Impact Fund: Making New Medicines Accessible for All. New Haven, CT: Incentives for Global Health. Available at http://www.healthimpactfund.org (accessed November 2011).
81. PEPFAR (US President's Emergency Plan for AIDS Relief). 2010. Report to Congress on Costs of Treatment in the President's Emergency Plan for AIDS Relief (PEPFAR). Washington, DC: PEPFAR.
82. Reddy, K.S. 2004. "Cardiovascular Disease in Non-Western Countries." New England Journal of Medicine 350(24): 2438-2440.
83. Riahi F. 2002. Quoted in "Encouraging the Development of Drugs for Poor, Not Just Rich, Nations." Summary of the Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy. Philadelphia: The Wharton School of the University of Pennsylvania. Available at http://knowledge.wharton.upen n.edu/article.cfm?articleid=644 (accessed January 2012).
84. Ridley, D.B, and A. Calles Sanchez. 2010. "Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases." The Lancet 376(9744): 922-927.
85. Ridley, D.B., H.G. Grabowski, and J.L. Moe. 2006. "Developing Drugs for Developing Countries." Health Affairs 25(2): 313-324.
86. Ridley, R. 2003. "Product R&D for Neglected Diseases: Twenty-Seven Years of WHO/TDR Experiences with Public-Private Partnerships." European Molecular Biology Organization Reports 4: S43-S46.
87. Rollings, M. 2007. "Combating Counterfeit Drugs: An International Problem." Drug Topics 151(19): 30-32.
88. Sabot O.J., A. Mwita, J.M. Cohen, Y. Ipuge, M. Gordon, D. Bishop, M. Odhaimbo, L. Ward, and C. Goodman. 2009. "Piloting the Global Subsidy: The Impact of Subsidized Artemisinin-Based Combination Therapies Distributed Through Private Drug Shops in Rural Tanzania." PLoS ONE 4(9): e6857.
89. Sehgal, S. 2002. "Private Equity Investments in Pharmaceuticals: An Asian LDC Perspective." Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy. Philadelphia: The Wharton School of the University of Pennsylvania.
90. Seiter, A. (2008). "IPRs and Access to 'New Essential Drugs.' " Geneva and Washington DC: International Health Partnerships/the World Bank. Available at http://siteresources.worldbank.org/INTHSD/Resources/Presentations/454393- 1249391374015/IPRsandAccesstoNewEssentialDrugsJune2008.pdf (accessed January 15, 2012).
91. Shah, R. 2002. "Accelerating the Introduction of New Vaccines into Developing Countries." Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy. Philadelphia: The Wharton School of the University of Pennsylvania.
92. Towse, A., and H. Kettler. 2005a. "A Review of IP and Non-IP Incentives for R&D for Diseases of Poverty: What Type of Innovation Is Required and How Can We Incentivise the Private Sector to Deliver It?" Working Paper for the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva: World Health Organization.
93. Towse, A., and H. Kettler. 2005b. "Advance Price or Purchase Commitments to Create Markets for Treatments for Diseases of Poverty: Lessons from Three Policies." Bulletin of the World Health Organization 83: 301-307.
94. Trouiller P., P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford. 2002. "Drug Development for Neglected Diseases: A Deficient Market and a Public- Health Policy Failure." Lancet 359(9324): 2188-2194.
95. UNITAID. 2010. "UNITAID Statement on the Medicines Patent Pool." Geneva: WHO. Available at http://www.unitaid.eu/en/20100722271/News/UNITAID-STATEMENT-ON-THE-MEDICINES-PATENT-POOL.html (accessed August 25, 2010)
96. Vilela, C. 2002. "Private Equity Venture Capital Market: Ingredients for Success." Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy. Philadelphia, PA.
97. Wagstaff, A., M. Lindelow, et al. 2009. "Extending Health Insurance to the Rural Population: An Impact Evaluation of China's New Cooperative Medical Scheme." Journal of Health Economics 28(1): 1-19.
98. Watal, J. 2000. "Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPS Agreement." World Economy 23(5): 733-752.
99. Weiner, D. 2002. "HIV-1, High Technology DNA Vaccines and the Developing World, A Match?" Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy. Philadelphia: The Wharton School of the University of Pennsylvania.
100. World Health Organization. 2008. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. Resolution WHA 61.21, Sixty- First World Health Assembly, Geneva: WHO.
101. World Health Organization. 2010. Research and Development: Coordination and Financing. Report of the World Health Organization Expert Working Group on Research and Development Financing. Geneva: WHO. Available at www.who.int/phi/documents/ewg_report/(accessed November 2011).
102. Wilson, P., and A. Palriwala. 2010. Prizes for Global Health Technologies: An Assessment with a Case Study on TB Diagnostics. Consultation draft. Washington, DC: Results for Development Institute, Center for Global Health R&D Policy Assessment.
103. Witty, A. 2010. "Open Labs, Open Minds: Breaking Down the Barriers to Innovation and Access to Medicines in the Developing World." Speech to Council on Foreign Relations. New York, NY. January 20, 2010. http://www.cfr.org/poverty/open-labs-open-minds-breaking-down-barriersinnovation- access-medicines-developing-world/p21273 (accessed January 3, 2012)
104. Yach, D., D. Struckler, and K.D. Brownell. 2006. "Epidemiologic and Economic Consequences of the Global Epidemics of Obesity and Diabetes." Nature Medicine 12(1): 62-66.
105. Yadav P. 2010. Differential Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings and Ideas for Action. A study conducted for the UK Department for International Development. London: UK DFID.
106. Yadav, P., K. Curtis, and N. Sekhri. 2007. Mapping and Realigning Incentives in the Global Health Supply Chain. Washington, DC: Center for Global Development.
107. Yin, W. 2008. "Market Incentives and Pharmaceutical Innovation." Journal of Health Economics 27(4): 1060-1077.
108. Zeckhauser, R. 2002. "Health Externalities from LDC Pharmaceutical Use." Wharton Impact Conference: Pharmaceutical Innovation in the Global Economy. Philadelphia: The Wharton School of the University of Pennsylvania.
109. Zhou, B., L. Yang, Q. Sun, H. Gu, and B. Wang. 2008. "Social Health Insurance and Drug Spending Among Cancer Inpatients in China." Health Affairs 27(4): 1020-1027.